GlassScriptPhysician profile
Julio Cantero
NPI 1821060682
$811,017.33
in general payments reported to CMS, 2019-2025
65 companies · $166K in 2025
The $166K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $54K · 2021: $149K · 2022: $123K · 2023: $91K · 2024: $122K · 2025: $166K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $268K · Travel and Lodging: $57K · Food and Beverage: $24K · Honoraria: $21K · Consulting Fee: $8,900 · Education: $43.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $268,338.25 |
| Travel and Lodging | $56,756.20 |
| Food and Beverage | $24,257.84 |
| Honoraria | $20,875.00 |
| Consulting Fee | $8,899.78 |
| Education | $43.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $104,192.10 | 2019-2025 | Fintepla, Nayzilam, Briviact |
| Otsuka America Pharmaceutical, INC. | $103,555.49 | 2024-2025 | Rexulti |
| Eisai INC. | $95,094.19 | 2019-2025 | |
| Abbvie INC. | $92,481.82 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Jazz Pharmaceuticals INC. | $85,828.11 | 2019-2025 | Epidiolex, Xywav |
| Biohaven Pharmaceuticals, INC. | $73,602.66 | 2020-2021 | |
| Neurelis, INC. | $71,651.27 | 2020-2025 | Valtoco |
| Sk Life Science, INC. | $62,873.77 | 2020-2025 | Xcopri |
| Biohaven Pharmaceutical Holding Company LTD. | $37,297.30 | 2022 | |
| Allergan, INC. | $18,774.90 | 2019-2021 | |
| Greenwich Biosciences, INC. | $17,536.86 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $12,444.77 | 2023-2025 | Fycompa |
| Pfizer INC. | $11,376.68 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $7,026.90 | 2019-2025 | |
| Inspire Medical Systems, INC. | $2,527.58 | 2021-2025 | Inspire |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $2,505.96 | 2019-2022 | |
| Livanova USA, INC. | $2,398.03 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Medtronic, INC. | $1,704.82 | 2025 | Visualase, Percept PC Brainsense |
| Amgen INC. | $1,141.45 | 2019-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $907.45 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $687.26 | 2019-2025 | Rexulti, Vyepti |
| Aquestive Therapeutics, INC. | $660.00 | 2021 | |
| Boston Scientific Corporation | $410.46 | 2022-2023 | Eluvia, Coyote Es |
| Lilly USA, LLC | $377.30 | 2019-2025 | Kisunla, Zepbound |
| Harmony Biosciences LLC | $330.04 | 2020-2024 | Wakix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $308.32 | 2023-2025 | Rexulti |
| Genzyme Corporation | $240.00 | 2021 | |
| Axsome Therapeutics, INC. | $232.61 | 2025 | Symbravo |
| Merck Sharp & Dohme LLC | $231.91 | 2021-2023 | Belsomra |
| Sumitomo Pharma America, INC. | $207.03 | 2023-2024 | Aptiom |
| Biogen, INC. | $194.40 | 2021-2025 | Vumerity, Tysabri |
| Centinel Spine, LLC | $154.71 | 2022 | |
| Portola Pharmaceuticals, LLC | $141.83 | 2019 | |
| Acorda Therapeutics, INC | $138.46 | 2019-2024 | Inbrija |
| Mdd US Operations, LLC | $134.37 | 2025 | Qelbree, Gocovri |
| Supernus Pharmaceuticals, INC. | $106.60 | 2019-2022 | |
| Genentech, INC. | $103.54 | 2023 | Ocrevus |
| Amneal Pharmaceuticals LLC | $102.21 | 2019-2024 | Rytary |
| Impel Pharmaceuticals LLC | $94.48 | 2025 | Trudhesa |
| Acadia Pharmaceuticals INC | $88.46 | 2019-2025 | Daybue |
| Genentech USA, INC. | $85.92 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Neurocrine Biosciences, INC. | $84.84 | 2024-2025 | Ingrezza |
| Nuvasive, INC. | $82.15 | 2019 | |
| Argenx US, INC. | $77.95 | 2023 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $74.12 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $65.20 | 2021-2024 | Andexxa |
| Arbor Pharmaceuticals, INC. | $56.25 | 2022 | |
| Alnylam Pharmaceuticals INC. | $53.87 | 2022 | |
| Emd Serono, INC. | $52.86 | 2019 | |
| Impel Pharmaceuticals INC. | $48.62 | 2022 | |
| Merz Pharmaceuticals, LLC | $43.50 | 2022-2025 | Inbrija, Xeomin |
| Strongbridge US INC. | $43.45 | 2019 | |
| Alexion Pharmaceuticals, INC. | $41.83 | 2021-2025 | Ultomiris |
| Azurity Pharmaceuticals, INC. | $39.74 | 2023-2024 | Horizant, Horizant |
| Janssen Biotech, INC. | $37.12 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.44 | 2020-2021 | |
| Resmed Corp | $32.15 | 2019-2023 | |
| Zyla Life Sciences, INC. | $32.14 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $30.33 | 2022 | |
| Microtransponder, INC. | $28.79 | 2025 | |
| C2n Diagnostics, LLC | $25.99 | 2025 | Precivityad2 |
| Ge Healthcare | $25.43 | 2025 | |
| Banner Life Sciences, LLC | $20.80 | 2022 | |
| Aucta Pharmaceuticals, INC. | $20.59 | 2025 | Motpoly Xr |
| Celgene Corporation | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Cantero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.